A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial

Pharmaceutical Statistics

Volumn 14, Issue 4, 2015, Pages 302-310

  Wages, Nolan A ^a   Read, Paul W ^a   Petroni, Gina R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

adaptive design; dose finding; heterogeneity; optimal dose; Phase I; Phase I II

Indexed keywords

ADAPTIVE DESIGN; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; DOSIMETRY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RADIATION SAFETY; RETREATMENT; SAMPLE SIZE; SIMULATION; STEREOTACTIC BODY RADIATION THERAPY; STUDY DESIGN; ADVERSE EFFECTS; BONE NEOPLASMS; COMPUTER SIMULATION; HUMAN; METHODOLOGY; PALLIATIVE THERAPY; PROCEDURES; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY DOSAGE; RISK ASSESSMENT; SECONDARY; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TREATMENT OUTCOME;

BONE NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL; PALLIATIVE CARE; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY DOSAGE; RESEARCH DESIGN; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937023007     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1686     Document Type: Article

References (30)

1. Braun T,. The current design of oncology Phase I clinical trials: progressing from algorithms to statistical models. Chinese Clinical Oncology 2014; 3: 2.
2. Thall PF, Nguyen HQ, Braun T, Qazilbash MH,. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics 2013; 69: 673-682.
3. Wages NA, Conaway MR,. Phase I/II adaptive design for drug combination oncology trials. Statistics in Medicine 2014; 33: 1990-2003.
4. Zang Y, Lee JJ, Yuan Y,. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clinical Trials 2014; 11: 319-327.
5. Ramanathan R, Egorin M, Takimoto C, Remick S, Doroshow J, LoRusso P, et al., Phase I and pharmacokinetic study of Imatinib Mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. Journal of Clinical Oncology 2008; 26: 563-569.
6. LoRusso P, Venkatakrishnan K, Ramanathan R, Sarantopoulos J, Mulkerin D, Shibata S, et al., Pharmacokinetics and safety of Bortezomib in patients with Advanced malignancies and varying degrees of liver dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clinical Cancer Research 2012; 18: 1-10.
7. Dasari A, Gore L, Messersmith W, Diab S, Jimeno A, Weekes C, et al., A Phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Investigational New Drugs 2013; 31: 115-125.
8. Prados M, Chang S, Burton E, Kapadia A, Rabbitt J, Page M, et al., Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proceedings of the American Society of Clinical Oncology 2003; 22, (abstract 394).
9. Ura T, Satoh T, Tsujinaka T, Sasaki Y, Yamazaki K, Munakata M, et al., Phase I study of irinotecan with individualized dosing based on UGT1A1 polymorphism in Japanese patients with gastrointestinal cancer. (UGT0601). Journal of Clinical Oncology 2008; 26, (May 20 suppl; abstr 14502).
10. Kim T, Sym S, Lee S, Ryu M, Lee J, Chang H, et al., A UGT1A1 genotype-directed Phase I study of irinotecan (CPT-11) combined with fixed dose of capecitabine in patients with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2009, Vol 27, No 15S (May 20 Supplement): 2554.
11. O'Quigley J, Pepe M, Fisher L,. Continual reassessment method: a practical design for Phase I clinical trials in cancer. Biometrics 1990; 46: 33-48.
12. O'Quigley J, Shen LZ, Gamst A,. Two sample continual reassessment method. Journal of Biopharmaceutical Statistics 1999; 9: 17-44.
13. Legezda A, Ibrahim J,. Heterogeneity in Phase I clinical trials: prior elicitation and computation using the continual reassessment method. Statistics in Medicine 2001; 20: 867-882.
14. O'Quigley J, Paoletti X,. Continual reassessment method for ordered groups. Biometrics 2003; 59: 430-440.
15. Yuan Z, Chapell R,. Isotonic designs for Phase I cancer clinical trials with multiple risk groups. Clinical Trials 2004; 1: 499-508.
16. Ivanova A, Wang K,. Bivariate isotonic design for dose-finding with ordered groups. Statistics in Medicine 2006; 25: 2018-2026.
17. Thall PF, Nguyen HQ, Esty EH,. Patient-specific dose finding based on bivariate outcomes and covariates. Biometrics 2008; 64: 1126-1136.
18. Morita S,. Application of the continual reassessment method to a Phase I dose-finding trial in Japanese patients: East meets West. Statistics in Medicine 2011; 30: 2090-2097.
19. O'Quigley J, Iasonos A,. Dose-finding designs based on the continual reassessment method. In Handbook of Statistics in Clinical Oncology, (3rd ed), Crowley J, Hoering A,. CRC Press. Taylor & Francis Group: Boca Raton, FL; 2006; pp. 21-51.
20. Shu J,. CRM designs in the presence of patient heterogeneity (Unpublished doctoral dissertation). University of Virgina: Charlottesville, VA, 2013.
21. O'Quigley J, Iasonos A,. Bridging solutions in dose finding problems. Statistics in Biopharmaceutical Research 2014; 6: 185-197.
22. Lee SM, Cheung YK,. Model calibration in the continual reassessment method. Clinical Trials 2009; 6: 227-238.
23. Thall PF, Nguyen HQ,. Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes. Journal of Biopharmaceutical Statistics 2012; 22: 785-801.
24. O'Quigley J, Zohar S,. Retrospective robustness of the continual reassessment method. Journal of Biopharmaceutical Statistics 2010; 5: 1013-1025.
25. R Core Team,. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria, 2013; ISBN 3-900051-07-0, Available at: http://www.R-project.org (accessed 18.6.2014).
26. Cheung K,. dfcrm: Dose-finding by the continual reassessment method. R package version 0.2-2 2013. Available at: http://CRAN.R-project.org/package=dfcrm (accessed 18.6.2014).
27. By K, Qaqish B,. mvtBinaryEP: generates correlated binary data. R package version 1.0.1 2011. Available at: http://CRAN.R-project.org/package=mvtBinaryEP (accessed 18.6.2014).
28. Cai C, Yuan Y, Ji Y,. A Bayesian dose finding design for oncology clinical trials of combinational biological agents. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2014; 63: 159-173.
29. Wages NA, Tait C,. Seamless Phase I/II adaptive design for oncology trials of molecularly targeted agents. Journal of Biopharmaceutical Statistics 2014, [epub ahead of print], DOI: 10.1080/10543406.2014.920873.
30. O'Quigley J, Conaway MR,. Extended model-based designs for more complex Phase I clinical trials. Statistics in Medicine 2011; 30: 2062-69.